Page 131 - Read Online

Akinci et al. Vessel Plus 2021;5:56 https://dx.doi.org/10.20517/2574-1209.2021.20 Page 7 of 20

Table 1. Summary of randomized clinical trials evaluating treatment of acute hypertensive response in patients with intracerebral hemorrhage

Opinion Intensive BP lowering group Conservative BP lowering
on early
intensiv Outcom
e Time Outcom
e
antihper Eligibilit frame Antihyp Follow- Number Time Time to Number Time Time to Primary intensiv e
tensive Trial Patients y BP for ertensiv up time of Target from achieve of Target from achieve outcome e/active standard
therapy (mmHg) treatme e drugs patients BP onset to targeted patients BP onset to targeted treatme /control
accordin nt (ICH) (mmHg) treatme BP (ICH) (mmHg) treatme BP group
g to nt nt nt group
study
results

Supporte INTERAC ICH SBP 150- 6 h Urapidil, 90 days 203 < 140 240 min Within 1 h 201 < 180 280 min - Proportio Mean Mean
[38]
d T , patients 220 labetalol, in 42% of nal proportio proportio
2008 phentola patients change in nal nal
mine, and within hematom haemato haemato
nicardipin 6 h 66% a volume ma ma
e, nitrates of at 24 h growth growth
(IV and patients was 13.7% was
patch), 36.3%
hydralazin
e,
metoprolo
l, diuretics
Neutral Koch et al. ICH MAP ≥ 8 h Labetalol, 90 days 21 MAP< 110 3.2 ± 2.2 h 163.5 ± 21 MAP 110- 3.2 ± 2.2 h 87.1 ± Clinical 11.9 ± 29.7 18.2 ±
[52]
, 2008 patients 110 nicardipin 163.8 min 130 59.6 min deteriorati percent 46.8
e, sodium on (NIHSS average percent
nitropruss score increase average
ide drop ≥ 2 in ICH increase
points) volume in ICH
within the and 25.7 ± volume
first 48 h. 45.5 in and 35.7 ±
Hematom edema 48.7 in
a volume, edema
enlargeme no volume,
nt at 24 h significant no
was a difference significant
secondary s in early difference
endpoint neurologic s in early
al neurologic
deteriorati al
on and deteriorati
clinical on and
outcomes clinical
at 90 days outcomes
at 90 days